Remix Therapeutics’ REM-422, a First-in-Class mRNA Degrader of the MYB Oncogene, Demonstrates Anti-tumor Activity in Xenograft Models of Adenoid Cystic Carcinoma and Acute Myeloid Leukemia Portfolio News / By Libby Nunan Remix Therapeutics’ REM-422, a First-in-Class mRNA Degrader of the MYB Oncogene, Demonstrates Anti-tumor Activity in Xenograft Models of Adenoid Cystic Carcinoma and Acute Myeloid Leukemia Read More »
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Portfolio News / By Libby Nunan Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Read More »
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Portfolio News / By Libby Nunan Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Read More »
Kimia Therapeutics Appoints Imran S. Haque, Ph.D. as Chief Technology Officer Portfolio News / By Libby Nunan Kimia Therapeutics Appoints Imran S. Haque, Ph.D. as Chief Technology Officer Read More »
